LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Implementation of the Net-Zero Industry Act

20/02/2025

PUBLIC CONSULTATION

Implementation of the Net-Zero Industry Act

EuropaBio comments on the list of net-zero technology final products and their main specific components

EuropaBio, the industry association for biotechnology in Europe, welcomes the opportunity to comment on the Implementing Act on the list of net-zero technology final products and main specific components.

We fully support the inclusion of microorganisms and enzymes in both final products and as main specific components under Biotech Climate and Energy Solutions. Industrial biotechnology and biomanufacturing are substantial contributors to net-zero, for example, by replacing a non-renewable resource by a bio-based resource and/or by using techniques such as fermentation which are generally less energy-intensive than conventional processes. An example is the production of vitamin B2, which reduces the use of fossil raw materials by 70% and wastewater by 65%, while reducing production costs by 40%. Other examples include the use of enzymes to replace chlorine in paper bleaching which reduces energy needs by 40% or in detergents to allow the use of lower temperatures during laundry and consequently a reduction of electricity use by 30%.

An important consideration for Biotech climate and energy solutions is the feedstock used in the process. Biomanufacturing processes using microorganisms and enzymes (in scope of the NZIA) can use biogenic carbon as well as recycled carbon and carbon capture and use (CCU, also falling in scope of the NZIA). The list of final products and main specific components currently only captures biogenic feedstock for biotech climate and energy solutions. This should be expanded to reflect additional sources of carbon that support the overall defossilisation of EU industry.

We would therefore like to submit some specific comments to further clarify and strengthen the criteria for final products and main specific components under Biotech climate and energy solutions. Please see below and attached in Annex.

  • ‘methanogens’ should be replaced by Archaea, to be consistent with the other broad classifications of microorganisms.
  • ‘microbial strains’ is a descriptor of specific lineages of microorganisms. It would be more accurate to either delete this, or move outside of the parenthesis i.e. “Microorganisms and microbial strains (such as bacteria, yeasts, …)”
  • Biopolymers and recycled carbon fuels, recycled carbon chemicals, and renewable fuels produced by fermentation using recycled or non-organic carbon sources should be added alongside biofuels, bio-based chemicals, bio-based materials and bio-based products: “convert feedstock into biofuels, recycled carbon fuels and renewable fuels, bio-based and recycled carbon chemicals, biopolymers, bio-based materials, and bio-based products.”
  • Specific examples are outlined for enzymes (amylase and cellulase). We understand that this is to provide examples without introducing limitations through a prescriptive list, which would not be future proof. We suggest amending the text accordingly to read “Enzymes (including but not limited to amylase and cellulase)”.

For the full response and the Annexes, please download the full document below.

Implementation of the Net-Zero Industry Act EuropaBio comments on the list of net-zero technology final products and their main specific components


Download
Share
Adrian Lincoln
Adrian Lincoln

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.